// App-Quantinova.ai

e18845 : Cost-effectiveness of apixaban versus other direct oral anticoagulants and low-molecular-weight-heparins for cancer associated venous thromboembolism in Spain.

Researchers

Presenter

  • Andres J. Muoz Martn

Principal Investigators

  • Enrique Gallardo Daz

  • Carlos Crespo

  • Roma Masana Domenech

  • Javier Soto

  • Daniel Arumi

  • Susana Fernandez

Medical Centers

  • Laboratorio de Inmuno-Metabolismo, Hospital General Universitario Gregorio Maranon, Instituto de Investigacion Sanitaria Gregorio Maranon, Madrid, Spain

  • Department of Oncology, Parc Tauli Sabadell Hospital Universitari, Institut dInvestigatio i Innovacio Parc Tauli I3PT, Universitat Autonoma de Barcelona, Sabadell, Spain

  • Axentiva Solutions S.L., Tacoronte, Spain

  • Pfizer Spain, Madrid, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • apixaban

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved